# Phylo launches Target Atlas for drug target prioritization with Parkinson’s edition

Digest AI · Enterprise & Industry · published 2026-09-29T08:26:00Z

Canonical: https://digestai.news/story/phylo-launches-target-atlas-for-drug-target-prioritization-with-parkin

## Summary

Phylo released **Target Atlas** on September 29, 2026, an AI-powered tool built on its **Biomni Lab** platform. The application speeds up target prioritization in drug development by reducing evidence-gathering from months to days. It uses AI agents to synthesize fragmented data from genetics, clinical activity, safety, and literature, while scientists retain control over weighting evidence and adjusting rankings. A free public edition covers thousands of target-disease assessments, while the first disease-specific version focuses on Parkinson’s, developed with **The Michael J. Fox Foundation**’s **Targets to Therapies (T2T)** initiative. The Parkinson’s edition connects to the foundation’s expert framework, which evaluated over **290 targets** and nominated **21** for feasibility in two to three years. The foundation’s **VP and head of translational therapeutics, Gaia Skibinski**, called the tool promising for accelerating target validation.

Phylo’s **enterprise edition** supports **20,000+ targets per disease**, proprietary data integration, and AI/ML scoring. The company plans to expand the public edition across diseases and seeks partnerships with foundations or consortia to sponsor additional free editions. Phylo, based in **South San Francisco**, raised a **$13.5 million seed round** co-led by **Andreessen Horowitz** and **Menlo Ventures’ Anthology Fund**, with backing from **Anthropic**. The tool is available at [biomni.phylo.bio](http://biomni.phylo.bio).

## Key points

- Phylo’s Target Atlas cuts drug target prioritization from months to days using AI agents and expert-weighted evidence
- Parkinson’s edition launched with The Michael J. Fox Foundation’s T2T initiative, covering 21 nominated targets from 290 evaluated
- Enterprise version supports 20,000+ targets per disease with proprietary data integration, priced via annual license

## Why it matters

Target Atlas automates a bottleneck in drug development—evidence synthesis for target prioritization—while preserving expert judgment. Its Parkinson’s edition aligns with a foundation-backed framework, and its public version could democratize access to fragmented data for researchers.

## Sources

1. [Phylo’s Target Atlas Puts AI Agents on Drug Target Prioritization](https://unite.ai/phylos-target-atlas-puts-ai-agents-on-drug-target-prioritization) (Unite.AI, 2026-09-29)

## Cite

Digest AI, "Phylo launches Target Atlas for drug target prioritization with Parkinson’s edition", 29 September 2026, https://digestai.news/story/phylo-launches-target-atlas-for-drug-target-prioritization-with-parkin

---

Written by Digest AI's editorial model from the linked sources; the sources are the record. Headlines, digests and key points are written by Digest AI and may be quoted with a link to the story page. Linked articles belong to their publishers. Terms: https://digestai.news/terms#reuse
JSON: https://digestai.news/story/phylo-launches-target-atlas-for-drug-target-prioritization-with-parkin.json